Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
NCT06059469

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

Led by Jules Bordet Institute · Updated on 2025-07-18

20

Participants Needed

1

Research Sites

183 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.

CONDITIONS

Official Title

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent obtained before any study procedures
  • Female patients aged 18 years or older
  • Eastern Cooperative Oncology Group Performance Status of 0 to 2
  • Confirmed diagnosis of progressive metastatic triple-negative breast cancer
  • Measurable disease on 18F-FDG PET/CT within 2 weeks or brain MRI within 4 weeks for brain metastases
  • PSMA PET/CT must be performed before starting the next treatment line
Not Eligible

You will not qualify if you...

  • Pregnant or lactating patients
  • Presence of other active cancer diseases
  • Treatment with another investigational drug within 30 days
  • Metastatic disease limited only to the skin
  • Significant medical, neuro-psychiatric, or surgical conditions that may interfere with study completion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institut Jules Bordet

Brussels, Belgium

Actively Recruiting

Loading map...

Research Team

G

Géraldine Gebhart, MD

CONTACT

L

Loubna Taraji, Ms

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. | DecenTrialz